Search Results 751-760 of 17451 for SC
Michael Camilleri, M.D., D.Sc. Contact information: Irene Busciglio. 5072666615. Contact Usbusciglio.irene@mayo.edu. Closed for enrollment. More information ...
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life.
Boos SC. Physical child abuse: Recognition. https://www.uptodate.com/contents/search. Accessed Jan. 12, 2022. Child neglect: Evaluation and management ...
Darakjian AA, Bhutani M, Fairweather D, Kocsis SC, Fliess JJ, Khatib S, Weigel GJ, McCabe EJ, Balamurugan V, Perona EE, Gehin JM, Whelan ER, Jain A, Sledge ...
Subjects treated with an IV or SC prostacyclin pathway agent (e.g., epoprostenol, treprostinil, or iloprost) at any time prior to Baseline (use in vasoreactive ...
... (s.c.), or oral prostanoids, or guanylate cyclase stimulators within 7 days prior to baseline RHC, or planned treatment during the study period; Treatment ...
The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival ...
Michael Camilleri, M.D., D.Sc. Closed for enrollment. More information. Publications. Publications are currently not available. Additional contact information.
Lalla SC, Kumar AB, Lehman JS, Lohse CM, Brewer JD. Association of BRAF V600E Status of Incident Melanoma and Risk for a Second Primary Malignancy: A ...
Why gastroenterologists and hepatologists should be involved in treating obesity. Mayo Clinic gastroenterologist Michael Camilleri, M.D., D.Sc., discusses the ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!